Rapid Drug Susceptibility Testing

CPTR’s Rapid Drug Susceptibility Testing (RDST) objective is to accelerate the development of a WHO STAG-endorsed clinically useful in vitro diagnostic assay specific to rapid drug susceptibility testing of TB, and inform drug development and the rationale for new drug regimens. This work is done through generating and researching molecular data to drive the development of molecular DST assays, facilitating the development of rapid TB DSTs to meet target product profiles, improving the strategies for surveillance of TB drug resistance and developing models to provide insight on the impact of various components to TB drug regimens and trajectories with and without DST intervention.